This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision | ||
dag3 [2020/02/12 09:37] trynke |
dag3 [2023/02/14 08:57] (current) kevin |
||
---|---|---|---|
Line 10: | Line 10: | ||
===== Subcohort ===== | ===== Subcohort ===== | ||
- | A total of 9500 participants were included in the DAG3 dataset: | + | A total of approximately 9500 participants were included in the DAG3 dataset: |
* 700 were [[children]] aged 8-17 years | * 700 were [[children]] aged 8-17 years | ||
* 400 participants were also included in the ([[DEEP]]) dataset | * 400 participants were also included in the ([[DEEP]]) dataset | ||
- | * microbiome collection sites were more diverse | ||
* ~9000 participants were genotyped in the [[UGLI]] project. | * ~9000 participants were genotyped in the [[UGLI]] project. | ||
- | Metagenomic sequencing of the Lifelines DAG3 samples is underway to assess taxonomy, strain diversity and functionality. Uniquely, not only are all individuals fully genotyped but glycerol aliquots of their microbiota are also stored to enable bacterial culture for further functional studies. Lifelines DAG3 will have the power to study host-microbe interactions and will also allow studies to move from association to causality ((Doestzada, M., Vich Vila, A., Zhernakova, A., Koonen, D. P. Y., Weersma, R. K., Touw, D. J., ... Fu, J. | + | Metagenomic sequencing of the Lifelines DAG3 samples was performed to assess taxonomy, strain diversity and functionality. Uniquely, not only are all individuals fully genotyped but glycerol aliquots of their microbiota are also stored to enable bacterial culture for further functional studies. Lifelines DAG3 will have the power to study host-microbe interactions and will also allow studies to move from association to causality ((Doestzada, M., Vich Vila, A., Zhernakova, A., Koonen, D. P. Y., Weersma, R. K., Touw, D. J., ... Fu, J. |
(2018). Pharmacomicrobiomics: A novel route towards personalized medicine? Protein & cell, 9(5).)). | (2018). Pharmacomicrobiomics: A novel route towards personalized medicine? Protein & cell, 9(5).)). | ||
- | Besides the samples used to generate the microbiome data, questionnaires were also sent to participants to gather phenotypic data on GI health symptoms by means of [[Functional bowel symptoms (Rome III)|Rome III]] criteria questionnaire (Longstreth etal 2006) and the Bristol Stool Form Scale (O’Donnell etal 1990). | + | Besides the samples used to generate the microbiome data, questionnaires were also sent to participants to gather phenotypic data on gastrointestinal health symptoms by means of [[Functional bowel symptoms (Rome III)|Rome III]] criteria questionnaire (Longstreth etal 2006) and the Bristol Stool Form Scale (O’Donnell etal 1990). |
===== Study protocol ===== | ===== Study protocol ===== | ||
Line 27: | Line 26: | ||
* Signed DAG3 IC available | * Signed DAG3 IC available | ||
* Registration of participant | * Registration of participant | ||
- | * 1 x throat and 1 x nose swab with amysmedium | + | * 1 x throat and 1 x nose swab with amies liquid medium |
- | * 1 x throat and 1 x nose e-nat-swab with presercation solution for DNA-isolation | + | * 1 x throat and 1 x nose e-nat-swab with preservation solution for DNA-isolation |
* Swabs are stored in refrigerator at the visit location and processed/frozen within 48h | * Swabs are stored in refrigerator at the visit location and processed/frozen within 48h | ||
* Face-to-face instruction of stool collection | * Face-to-face instruction of stool collection | ||
Line 39: | Line 38: | ||
Participants received a package with the following materials: | Participants received a package with the following materials: | ||
* 3 precoded cups to put stool in by means of a provided pipet | * 3 precoded cups to put stool in by means of a provided pipet | ||
- | * 2 tubes with amysmedium and glycerol to put stool in with provided e-swabs, and two barcoded labels for the tubes | + | * 2 tubes with amies liquid medium and glycerol to put stool in with provided e-swabs, and two barcoded labels for the tubes |
- | * a nontransparent bag to store the samples in the home freezer immediately after collection. | + | * a nontransparent bag to store the samples in the home freezer immediately after collection |
+ | * participants were instructed to fill in a questionnaire and stool diary in the week of stool collection | ||
===== Sample processing ===== | ===== Sample processing ===== | ||
- | * Swabs containing amysmedium were processed into 3 aliquots, containing glycerol. The processing of swabs to aliquots was performed in a flow chamber to prevent contamination. Aliquots were be stored at -80C. | + | * Swabs containing liquid amies medium were processed into 3 aliquots, containing glycerol. The processing of swabs to aliquots was performed in a flow chamber to prevent contamination. Aliquots were stored at -80C. |
- | * Stool samples were taken in between 16:30 and 19:00 by hired personnel and transported to the Lifelines lab in cool boxes containing cooling elements. Collectors asked participants at home if they filled all three cups and two tubes and if not, the reason for an incomplete collection. At the Lifelines lab all cups and tubes are stored at -80C. | + | * Stool samples were taken in between 16:30 and 19:00 by hired personnel and transported to the Lifelines lab in refrigerated boxes containing cooling elements. Collectors asked the participants at home if they filled all three cups and two tubes and if not, the reason for an incomplete collection. At the Lifelines lab all cups and tubes were stored at -80C. |
- | * blood samples were collected in a PAXgene tube, by means of a ‘butterfly needle’. An empty dummy tube preceded the Paxgene tube. The Paxgene tube was transported to the Lifelines lab, registered and stored in -80C freezers. | + | * blood samples were collected in a PAXgene tube, by means of a ‘butterfly needle’. A "discard tube" was drawn preceding the PAXgene tube. The PAXgene tube was transported to the Lifelines lab, registered and stored at -80C. |
===== Collected samples ===== | ===== Collected samples ===== | ||
- | The following additional samples have been collected for DAG3: | + | The following additional samples have been collected for DAG3 from approximately 9500 participants: |
* 9535 e-nat nose samples | * 9535 e-nat nose samples | ||
- | * 9540 nose swab samples | + | * 28612 nose swab aliquots (glycerol)* |
- | * 28612 nose swab aliquots (glycerol) | + | |
* 9425 throat e-nat samples | * 9425 throat e-nat samples | ||
- | * 9421 throat swab samples | + | * 28245 throat swab aliquots (glycerol)* |
- | * 28245 throat swab aliquots (glycerol) | + | * 16827 feces swab samples* |
- | * 16827 feces swab samples | + | * 25376 feces cryo samples* |
- | * 25376 feces cryo samples | + | * 8931 PAXgene samples |
- | * 8931 paxgene samples | + | |
* 5400 complete diaries | * 5400 complete diaries | ||
* 2482 incomplete diaries (i.e. may miss one or more days) | * 2482 incomplete diaries (i.e. may miss one or more days) | ||
+ | *Multiple samples from a single participant, sourced from the nose- or throat swab. | ||
+ | ===== Papers based on DAG3 ===== | ||
+ | * Gacesa, R et al. (2022) Environmental factors shaping the gut microbiome in a Dutch population. Nature 604, 732–739 |